← All indications
Carcinoma, Ovarian Epithelial
A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.
Drugs by status
Approved for this indication (5)
Phase 4 trials (3)
Phase 3 trials (18)
Phase 2 trials (74)
- azacitidine
- anlotinib
- anetumab ravtansine
- astx660
- atovaquone
- avelumab
- mk-1775
- belinostat
- belotecan
- binimetinib
- talazoparib
- catumaxomab
- dc vaccine
- dcvac/ovca in parallel
- denileukin diftitox
- durvalumab
- e7777
- Pegfilgrastim
- entinostat
- farletuzumab
- fulvestrant
- fluoroestradiol
- epirubicin
- mitomycin
- iron sucrose
- ixabepilone
- lenvatinib
- seribantumab
- motolimod
- palbociclib
- +44 more
Phase 1 trials (69)
- saracatinib
- sfericase
- acetylcysteine
- bp1001
- irinotecan
- lenalidomide
- prednisone
- dpx-survivac
- fluorouracil
- aldesleukin
- hkt288
- ramucirumab
- imiquimod
- ipatasertib
- leucovorin
- lurbinectedin
- montanide isa51
- ny-eso-1 olp4
- survivin-peptide double loaded dendritic cells
- quisinostat
- cyclophosphamide
- abiraterone
- trk-950
- defactinib
- mesothelin car t cells
- fate-nk100
- flax
- spl-108
- fludarabine
- poly-iclc
- +39 more
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (17)
- Kalmar Central Hospital
- Tesaro
- Harvard University
- ARCAGY-GINECO
- Loyola University
- University of Milan
- Centre François Baclesse
- Mario Negri Institute
- Linkoping University
- University of Campania Luigi Vanvitelli
- Shandong University
- Zhejiang University
- Duke University
- Fondazione Giovanni Pascale
- Merck
- AstraZeneca
- University of Chicago
Organization Involved with Phase 3 Indications (141)
- Zai Lab Pty. Ltd.
- Aptiv Solutions
- Bristol-Myers Squibb
- Erasmus University Rotterdam
- University of Lille
- Swiss Group for Clinical Cancer Research
- Sequus Pharmaceuticals
- Gynecologic Oncology Trial & Investigation Consortium
- Chongqing Cancer Institute
- Swiss Go Trial Group
- University of Edinburgh
- Japanese Gynecologic Oncology Group
- University of Castilla-La Mancha
- Cancer and Leukemia Group B (CALGB)
- Universidad de Murcia
- Apices Soluciones S.L.
- University of Genoa
- Impact Therapeutics, Inc.
- Unither Pharmaceuticals
- Medical Research Council
- Theradex
- Southern Medical University
- Government of Colombia
- University of Calgary
- Endocyte
- Facing Our Risk of Cancer Empowered
- Chinese Academy of Medical Sciences
- Universidad Complutense de Madrid
- Gradalis, Inc.
- SCRI Development Innovations
- +111 more
Organization Involved with Phase 2 Indications (341)
- University of Alabama, Birmingham
- Mid-Atlantic Gynecologic Oncology & Pelvic Surgical Associates
- University of Miami
- Icahn School of Medicine at Mount Sinai
- Charles University
- University of Queensland
- Austin Health
- Qingfeng Pharmaceutical Group
- The Cancer Research Society
- SmithKline Beecham
- French Cancer Research Hospital Program
- Innovation Pharmaceuticals
- Memorial Sloan-Kettering Cancer Center
- Gynecologic Oncology Trial and Investigation Consortium, Japan
- Astex Pharmaceuticals, Inc.
- TetraLogic Pharmaceuticals
- Latin American Cooperative Oncology Group
- Temple University
- Gynecologic Oncology Associates
- Alcedis GmbH
- Ellipses Pharma
- AB Science
- New York Presbyterian Hospital
- ExcellaBio LLC
- University of Alberta
- University of Warwick
- ISTITUTO REGINA ELENA
- NewLink Genetics Inc
- University of Western Australia
- University of Pittsburgh
- +311 more
Organization Involved with Phase 1 Indications (87)
- Biontech
- Kom Op Tegen Kanker
- ImmunoVaccine Technologies, Inc.
- University of Kentucky
- Medivation
- Southern Illinois University
- Department of Defense
- Rigel Pharmaceuticals
- Asana BioSciences
- Wyeth
- ICON
- Institut Bergonié
- PTC Therapeutics
- Xencor
- Ohio State University
- Lee's Pharmaceutical
- University of Tuebingen
- Novella Clinical
- GenScript
- National Hospital Organisation Shikoku Cancer Centre
- University of Bergen
- Allife Medical Science and Technology Co., Ltd.
- Dr. Reddy's Laboratories
- Puma Biotechnology, Inc.
- Lambda Therapeutic Research Ltd
- Azaya Therapeutics, Inc
- MaxCyte, Inc.
- IRCCS CANDIOLO
- Beijing Tumor Hospital
- Genelux
- +57 more
Organization Involved with Other Experimental Indications (7)